Suppr超能文献

神经病理学在进展性胶质母细胞瘤管理中的作用:系统评价和基于证据的临床实践指南。

The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

机构信息

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA,

出版信息

J Neurooncol. 2014 Jul;118(3):461-78. doi: 10.1007/s11060-013-1331-z. Epub 2014 Apr 15.

Abstract

QUESTION

  1. What are the most important diagnostic considerations in reporting progressive glioblastoma?

TARGET POPULATION

These recommendations apply to adults with progressive glioblastoma

LEVEL III

For patients who undergo biopsy or neurosurgical resection at the time of radiologic or clinical progression, it is recommended that the pathologist report the presence and extent of progressive neoplasm as well as the presence and extent of necrosis within the pathologic material examined. Furthermore, to ensure the proper interpretation of progressive glioblastoma, it is recommended that the pathologist take into account the patient's previous diagnosis and treatment, as well as the current clinical and neuroimaging features that have led to a second biopsy or resection.

QUESTION

  1. What techniques and ancillary studies are most useful in separating malignant progression from treatment effect?

TARGET POPULATION

These recommendations apply to adults with progressive glioblastoma

LEVEL III

In the setting of prior radiation and chemotherapy, it is recommended to adhere to strict histologic criteria for microvascular proliferation and necrosis in order to establish a diagnosis of a glioblastoma. Immunohistochemistry and genetic studies are selectively recommended for distinguishing neoplastic cells from atypical reactive cells in progressive glioblastoma.

摘要

问题

  1. 在报告进展性胶质母细胞瘤时,最重要的诊断考虑因素有哪些?

目标人群

这些建议适用于进展性胶质母细胞瘤的成年患者。

级别 III:对于在影像学或临床进展时接受活检或神经外科切除的患者,建议病理学家报告进行检查的病理材料中进展性肿瘤的存在和范围,以及坏死的存在和范围。此外,为了确保正确解读进展性胶质母细胞瘤,建议病理学家考虑患者之前的诊断和治疗,以及导致第二次活检或切除的当前临床和神经影像学特征。

问题

  1. 哪些技术和辅助研究在区分恶性进展与治疗效果方面最有用?

目标人群

这些建议适用于进展性胶质母细胞瘤的成年患者。

级别 III:在先前进行过放疗和化疗的情况下,建议坚持严格的微血管增生和坏死的组织学标准,以确立胶质母细胞瘤的诊断。建议选择性地进行免疫组织化学和基因研究,以区分进展性胶质母细胞瘤中的肿瘤细胞与非典型反应性细胞。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验